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Abstract
Background: Emerging evidence suggests that a subset of FMR1 premutation carriers is at an increased risk for
cognitive, emotional, and medical conditions. However, because the premutation is rarely diagnosed at birth, the
early developmental trajectories of children with a premutation are not known.
Methods: This exploratory study examined the cognitive, communication, and social-behavioral profiles of 26
infants with a premutation who were identified through participation in a newborn screening for fragile X syndrome
pilot study. In this study, families whose newborn screened positive for an FMR1 premutation were invited to
participate in a longitudinal study of early development. Twenty-six infants with the premutation and 21 matched,
screen-negative comparison babies were assessed using validated standardized measures at 6-month intervals starting
as young as 3 months of age. The babies were assessed up to seven times over a 4-year period.
Results: The premutation group was not statistically different from the comparison group on measures of cognitive
development, adaptive behavior, temperament, or overall communication. However, the babies with the premutation
had a significantly different developmental trajectory on measures of nonverbal communication and hyperresponsivity
to sensory experiences. They also were significantly more hyporesponsive at all ages than the comparison group.
Cytosine-guanine-guanine repeat length was linearly associated with overall cognitive development.
Conclusions: These results suggest that infants with a premutation may present with subtle developmental
differences as young as 12 months of age that may be early markers of later anxiety, social deficits, or other challenges
thought to be experienced by a subset of carriers.
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Background
Individuals with premutation range cytosine-guanine-
guanine (CGG) repeats (55–200) on the fragile X mental re-
tardation (FMR1) gene were originally considered unaffected
carriers whose primary health risk was the chance of off-
spring with fragile X syndrome (FXS). However, individuals
with a premutation (“carriers”) are now known to be vulner-
able to two later onset disorders—fragile X-associated
tremor/ataxia syndrome (FXTAS) [1, 2] and fragile X-
associated primary ovarian insufficiency (FXPOI) [3], and
may also be vulnerable to multiple other medical, emotional,
and cognitive challenges [4]. Population studies suggest a
high prevalence of the premutation, with as many as 1:150
women and 1:450 men estimated to be carriers [5–8]. This
increased risk of health concerns and high population preva-
lence has led to a growing interest in the premutation pheno-
type [9–12]. However, most research on the premutation has
focused on adults. Studies of children or adolescents nearly
all involve participants who were identified because of the
diagnosis of a close family member with FXS, biasing the
sample toward increased likelihood of challenges.
Consistent with referral bias, studies of children with
the premutation who were clinically referred (probands)
suggest increased rates of developmental problems com-
pared to noncarrier siblings [13–15] and carriers who
were nonprobands—identified through cascade testing
[16–18]. Further, increased risk for nonspecific develop-
mental delay among children with premutation has been
reported [19]. However, other studies report intact
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cognitive abilities in adults with a premutation without
FXTAS [20]. Subtle cognitive difficulties have been
reported among adults, most notably in executive func-
tioning [20, 21], working memory [22], visual-spatial
perceptual deficits [11], arithmetic [23, 24], speech flu-
ency [25], and pragmatic language [26].
Several studies have documented more attention
regulation, anxiety, and autism-like symptoms among
carriers compared to controls. Hunter and colleagues
[27] found that adult female carriers self-reported sig-
nificantly more symptoms of inattention, memory, and
poor self-concept compared to controls, although they
did not score lower on cognitive tests. Anxiety symp-
toms, including social avoidance, interpersonal sensitiv-
ity, shyness, and eye contact avoidance, have been
described in carriers, with up to 41 % reporting a life-
time diagnosis of an anxiety disorder [28, 29]. A higher
than expected rate of autism spectrum disorders (ASDs)
have also been reported for carriers [16, 18, 19, 30],
although all these studies had some level of bias. More
subtle ASD symptoms, such as social aloofness [28], rigid
perfectionism [31], and features of the broad autism
phenotype, have been described among carrier women
[26]. These findings, along with studies linking the protein
encoded by FMR1—the fragile X mental retardation pro-
tein (FMRP)—to the regulation of several pathways associ-
ated with autism [32–35], suggest a possible link between
FMR1 and autism-related phenotypes.
Because the premutation is rarely diagnosed in in-
fancy, only one study has examined early development.
This study examined 14 infants with the premutation
and found visual processing deficits similar to infants
with FXS, although their overall developmental scores
were higher than those with FXS [36]. The findings
suggested that deficits in spatiotemporal processing and
subsequent executive dysfunction in some adults with
the premutation may be present very early in life and
emphasize the importance of studies examining early
development of individuals along the spectrum of
FMR1 mutations.
Here, we report findings from a longitudinal study of
infants identified with a premutation in a pilot study of
newborn screening for FXS. This is a unique sample as
the babies were identified and initially assessed within
the first few months of life. Further, nearly all families
were naïve to FXS or the premutation prior to the birth
of their child and therefore had no preconceived infor-
mation regarding the development of children with a
premutation, and none of the babies were clinically
referred. We were primarily interested in the very early
cognitive, communication, and social-emotional devel-
opment of infants with the premutation compared with
screen-negative comparison infants. Given studies of
older children and adults with a premutation, we did not
expect to find significant differences in cognitive trajec-
tories; however, we hypothesized that a subsample of
infants with the premutation would demonstrate devel-
opmental differences compared to infants without a
premutation.
Methods
Procedures
With approval from the Institutional Review Board,
families were recruited in the postpartum unit within
24 h of the birth of their child. Recruitment took place
over 4 years at three university-affiliated hospitals.
Details about recruitment procedures and laboratory
assessments can be found in previously published re-
ports [8, 37]. To be included, the mother had to be at
least 15 years of age, fluent in either Spanish or English,
not undergoing stressful medical or personal circum-
stances, and not have infants in critical care for life-
threatening conditions or relinquished for adoption.
Newborns with a premutation allele were identified
using polymerase chain reaction (PCR) analysis as re-
ported by Tassone et al. [8]. Because the study was
intended as a pilot for newborn screening, the molecular
data collected reflects only the information necessary to
identify an FMR1 mutation; additional molecular mea-
sures including activation ratio and methylation status
were not assessed.
Out of the 12,709 infants screened across the three
sites, one baby screened positive for the presence of a
full mutation and 45 screened positive for the presence
of a premutation. Families of screen-positive children
were called by a medical geneticist or clinician specializ-
ing in FXS on the research team and offered a genetic
counseling appointment and confirmatory testing. Six-
teen families did not have confirmatory testing because
they declined further participation (n = 3), did not show
up for the diagnostic appointment (n = 2), declined re-
peat testing (n = 3), or were unable to be reached via
phone or mail (n = 8).
All families whose babies had a confirmed expansion
following the diagnostic testing were invited to join the
longitudinal component of the study. Twenty-eight
infants who screened positive for an FMR1 mutation
participated in at least one longitudinal assessment.
The baby with FXS and one baby who also screened-
positive for Klinefelter’s syndrome were not included in
the analyses, resulting in a total of 26 infants. A set of
comparison tests on demographic variables (maternal
age, marital status, race/ethnicity, maternal education)
and child CGG repeat length for families who partici-
pated in the longitudinal study and those who screened
positive but declined participation was conducted,
yielding no significant differences between participants
and nonparticipants [38] (Table 1).
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Following diagnostic confirmation, families who agreed
to participate in the follow-up study were scheduled for
their first assessment when the child was 6 months of age.
Assessments were scheduled at approximately 6-month
intervals. All assessments were conducted at the family’s
home or at a hospital/clinic-based setting. Assessors
were trained by a licensed psychologist on all measures.
For most assessments, the assessors were not blind to
diagnostic group; however, some measures were
double-scored by measure experts who were blind to
diagnostic grouping.
Participants
Of the 26 infants with a premutation who participated
in at least one assessment, 15 were female. Fifty-four
percent of the sample was Caucasian, 23 % was African
American, and 8 % was Hispanic. Two sets of twins both
with a premutation were included. The range of CGG
repeats in infants with the premutation was 55–125,
with the majority of the premutation alleles below 70
CGG repeats (77 %).
Because participants entered the study at different
times over the course of the 4-year enrollment period, as
well as some attrition (n = 6), infants were assessed any-
where between one and seven times (see Table 2). Com-
parison tests, chi-square frequency tests for categorical
variables and t tests for continuous variables, were run
to examine potential differences in family demographic
and child variables for families who stayed in the study
versus those who dropped out after at least one data col-
lection visit. We found no evidence for differences in
gender, race, mother’s education, age, or CGG repeat of
the infant (all p > .27).
All families who participated in the newborn screening
pilot study provided basic demographic information and
were told at the time of providing consent that they may
be asked to participate in a longitudinal study as a com-
parison family should their infant screen negative. Com-
parison infants were recruited from the sample of babies
who screened negative for any FMR1 expansion if they
were a match for a screen-positive baby based on loca-
tion (i.e., state of study site), gender, race and ethnicity,
maternal education, and family income.
Measures
Eight well-validated, standardized measures were used to
assess early cognitive development, language and com-
munication, social-emotional, and sensory behaviors.
Early cognitive development
The Mullen Scales of Early Learning [39] was adminis-
tered at each assessment. The Mullen is a standardized
developmental test for children birth to 68 months,
assessing multiple developmental domains including ex-
pressive and receptive language, gross and fine motor
skills, and visual processing. The Vineland Adaptive
Behavior Scales, Second Edition (VABS-II) [40] was also
completed in an interview format with the primary care-
giver at each assessment point to measure functional
behavior. The VABS-II provides parent reported infor-
mation on functional skills in the areas of daily living,
communication, socialization, and motor. Standard
scores for all domains, as well as overall composites,
were used for analyses for these measures.
Early language and communication
In addition to the broad measures of expressive and
receptive language derived from the Mullen Scales of
Early Learning (MSEL) and VABS-II, measures of more
subtle communication and language development were
included in the battery. The parent-reported MacArthur
Communicative Development Inventories, Second Edition
[41] (CDI) were used to assess more detailed informa-
tion regarding the infants’ word production and early
communicative intent. The CDI consists of two inven-
tories, each with two sections. The CDI/Words and
Gestures Inventory is for infants between the ages of 8
and 16 months. The inventory’s word section, which has
a 28-item list of phrases and a 396-word checklist, is
used to assess the infant’s production and understanding
of words and phrases. The gesture section covers 63
Table 1 Demographics of sample
Premutation sample
(n = 26)
Comparison sample
(n = 21)
Number of
assessments
76 48
Gender 15 females 15 females
11 males 6 males
Ethnicity 14 (54 %) White 12 (57 %) White
6 (23 %)
African American
5 (24 %)
African American
2 (8 %) Hispanic 2 (10 %) Hispanic
4 (15 %) other 2 (9 %) other
CGG repeat (range) 55–125 –
Table 2 Number of assessments at each age point, by group
Group 3–4 months 5–7 months 11–12 months 16–19 months 22–25 months 29–31 months 35–42 months
Premutation 3 22 18 10 10 5 11
Comparison 0 15 10 8 6 5 4
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gestures for communication, play, imitation of parents
and other adults, and activities with objects. The CDI/
Words and Sentences Inventory is for toddlers between
the ages of 16 and 30 months. The inventory’s word sec-
tion assesses vocabulary using a 680-word checklist. The
second part assesses the toddler’s use of possessives,
plurals, and tenses and development of complex sen-
tences. The Words and Gestures Inventory was used at
18, and 24 months, replacing the CDI/Words and
Gestures Inventory used at 12 months.
The Communication and Symbolic Behavior Scale
(CSBS) [42] was used to assess functional communica-
tion. The CSBS is a norm-referenced screening and
evaluation tool that helps determine the communicative
competence (use of eye gaze, gestures, sounds, words,
understanding, and play) of children with a functional
communication age between 6 and 24 months (chrono-
logical age from about 6 months to 6 years). The scale
yields three composite scores—social, speech, and sym-
bolic—and concurrent and predictive validity are well
established [42]. The caregiver report form and the dir-
ectly administered behavioral profile components of the
CSBS were administered. All direct administrations were
videotaped and double-scored by a speech language
pathologist with expertise in CSBS administration and a
trained research assistant. Both coders were blind to the
diagnostic status of the participants.
Social-emotional and sensory behaviors
Due to reports of an increased incidence of autism,
attention, and anxiety symptoms among older children
and adults with the premutation, several measures of
early social communication and sensory behaviors were
included. The Sensory Experiences Questionnaire [43]
was completed by the caregivers at each data collection
point to assess behavioral responses to common sensory
experiences (e.g., child dislikes cuddling). Thirty-three
items are used to calculate (as simple means) a total
score and subscales for hyperresponsiveness (14 items),
hyporesponsiveness (6 items), and sensory seeking (13
items). The Sensory Experiences Questionnaire (SEQ)
categorizes scores as “normal,” “at-risk,” or “deficient”
based on the number of standard deviations from the
mean score for the norming sample [44]. In addition,
two measures of autism symptoms were administered.
The First Years Inventory (FYI) [45] was completed
with participants assessed at 12 months. The FYI was
developed to assess the presence of behaviors at
12 months associated with the later development of an
autism spectrum disorder. Finally, for those whose last
assessment occurred after 24 months, the second edi-
tion of the Autism Diagnostic Observation Schedule-2
[46] (ADOS-2) was administered.
Data analysis
Correlations between CGG repeat length and all vari-
ables were examined for those in the premutation group,
as were comparison (t tests of continuous variables; chi-
square for categorical) tests between males and females.
For these analyses, we chose the assessment point at the
oldest age for each child. For comparison tests between
groups, standard scores on all measures were averaged
for each participant across all assessments they com-
pleted. Despite the small n, longitudinal data analyses
were collected at up to seven time points per child for a
total of 124 assessments, allowing us to run hierarch-
ical linear models (HLM) on selected variables. Given
the large number of potential measures, we selected
variables for HLM based on two criteria: (1) variables
related to potential differences reported in older indi-
viduals with a premutation (social, communication,
sensory) and (2) variables demonstrating some diver-
gent patterns upon preliminary descriptive analysis.
The primary hypotheses under examination focused on
the relationship of child age and diagnostic group to
the outcomes of interest. We tested for nonlinear
(quadratic) change over time, but there was no evi-
dence that such trends existed, so all models were sim-
plified to include only linear terms. We treated the
models for the child outcomes as two-level hierarchical
linear models where time is nested within child. Re-
peated observations of subjects introduce dependence
in the data. HLM manages this through the estimation
of random effects in addition to traditional regression
parameters [47]. The random effects provide estimates
for within subject variance to control for this depend-
ence. These models included random effects for the
intercept. In all models, age and the moderators were
grand mean centered, so any group differences are at
the mean of those variables. The data are coded so that
the premutation group is the reference. The group pa-
rameters in Table 4, then, provide the mean difference
between the groups; positive parameters indicate a
higher score in the comparison group and negative pa-
rameters indicate a higher score in the treatment
group. The parameter for age represents the change
over time for the comparison group. The interaction
indicates how much the premutation group deviated
from that rate. The absence of an interaction indicates
that the mean difference is constant across all ages and
the range of the moderator. Where interactions were
suggested, graphs were generated to illustrate the
findings.
Our small sample size provided a substantial barrier
to our statistical inferences. Basic statistical theory sug-
gests that parameter estimates in samples of this size
are likely to be unreliable (e.g., Gravetter and Wallnau
[48, p. 204]). Further, standard error is inversely related
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to sample size, so power decreases as sample size
decreases. Having repeated measurement and testing in
HLM framework provides an increase to statistical
power [49]. We produced regression diagnostics (e.g.,
residual and normality plots) for all of the statistical
models in the analysis. Examination of these plots indi-
cated that normality and homoscedasticity assumptions
were met and provided no suggestion of outliers.
The difficulties arising from the small sample size are
compounded by the relatively large number of dependent
variables. Typically, the possibility of false discovery as a
function of multiple testing leads researchers to make
adjustments to the critical values or p values for the re-
sults (see Benjamini and Hochberg [50] for a complete
discussion). We opted to make no adjustments, how-
ever. Adjusting for multiple testing is intended to con-
trol for type I error. Given the exploratory nature of
this study, we suggest that the uniqueness of this sam-
ple and the potential for these results to provide useful
effect size estimates for future research makes type II
error of greater concern, but readers should keep the
possibility of false discovery in mind.
Results
Developmental profiles
Average scores on the Mullen across diagnostic groups
were similar over time, with mean scores consistently
in the low average to average range for both groups.
There were no significant differences between diagnos-
tic groups on any of the MSEL domains (expressive lan-
guage, receptive language, fine motor, gross motor,
visual reception) at any time point. Parent-reported
adaptive behaviors measured by the VABS-II composite
and domain scores were age appropriate for both
groups across all age points. There was no significant
age-by-group interaction for any MSEL or VABS-II
domain. However, CGG repeat length was negatively cor-
related with overall (last administered) MSEL scores (−.39;
p = .05); children with higher repeats had lower overall
development. See Table 3 for mean scores across all as-
sessment points by group on the MSEL and VABS-II.
Language profiles
There were no differences between gender or diagnostic
groups at any age point on any of the CDI variables.
Scores on the parent report and the direct administered
CSBS suggested some differences between the groups
however. For the parent report version, across all time
points, babies with the premutation were reported to
display fewer gestures than the screen-negative babies.
On the direct assessment measure, babies with the pre-
mutation were rated as having fewer gestures, poorer
emotion and eye gaze, and more use of words than the
comparison babies (see Table 3). There was a significant
interaction between age and group status for the emo-
tion and eye gaze subscale (see Table 4), which measures
early social-emotional and nonverbal communication
behaviors. While the comparison infants gained skills on
this subscale over time, eventually reaching the ceiling
by 36 months, babies with the premutation did not show
the same increases in skills, resulting in decreasing
scaled scores over time (see Fig. 1 and Table 3).
Behavioral profiles
There were no significant differences between males and
females with a premutation on any of the behavior do-
mains. However, there were significant differences be-
tween diagnostic groups across all assessment points on
sensory seeking, with the babies with the premutation
displaying more sensory-seeking behaviors. There were
also significant differences between groups over time on
both hypo- and hyperresponsivity on the SEQ. There
were significant main effects for hyporesponsiveness,
with the premutation group more hyporesponsive at
every age point assessed (see Fig. 2). There was also a
significant interaction effect for hyperresponsiveness (see
Table 4); while the comparison group became less hyper-
responsive as they got older (a normative pattern), the
premutation babies became more hyperresponsive over
time (see Fig. 3).
Autism symptoms
There were no significant differences between groups on
any of the scales on the FYI. However, while none of the
comparison babies and just 4 % of the norming sample
for the FYI [51] scored above 98th percentile on the
total risk variable, almost a third of the premutation ba-
bies (27 %) scored in this range. Although there were
too few participants who completed an ADOS-2 to com-
pare statistically across groups, three out of the eight
premutation babies who were tested scored in the ele-
vated range, compared to none of the controls. There
were no gender differences on these measures.
Discussion
This exploratory study is the first to examine early
developmental profiles of infants with an FMR1 premu-
tation. Amid emerging evidence that premutation CGG
expansions on the FMR1 gene are associated with
increased risks for social, emotional, and medical diffi-
culties, understanding the early trajectories of these
risks is critical. We found that patterns of broad early
development did not differ significantly from matched
screened-negative babies. This was true for all of the
areas of development traditionally assessed by pediatri-
cians during well-baby visits. However, we found sig-
nificant differences in several important variables
related to social and sensory experiences as early as
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12 months of age in premutation babies. Infants with the
premutation had increased risk for social communication
differences as well as both hypo- and hyperresponsiveness
to stimuli when compared to both the comparison group,
as well as norming samples. These differences suggest a
profile of very early regulation challenges which may be
Table 3 Means and standard deviations on key measures across all assessment points
Assessment Premutation sample: mean (SD) Comparison sample: mean (SD) p value for test
Mullen ELCa 89.1 (14.6) 92.8 (17.7) .436
Mullen GMb 48.7 (11.0) 49.2 (14.3) .896
Mullen FM 46.0 (10.9) 49.5 (11.2) .287
Mullen VR 44.3 (11.4) 47.9 (12.0) .301
Mullen RL 44.9 (11.7) 45.0 (13.3) .979
Mullen EL 41.8 (10.2) 42.1 (12.3) .929
VABS-II ABCc 97.9 (10.7) 100.3 (9.0) .408
VABS-II communication 98.1 (12.3) 100.4 (8.1) .446
VABS-II daily living skills 100.5 (10.9) 100.5 (13.9) 1.00
VABS-II motor 98.0 (14.5) 100.1 (10.2) .564
VABS-II socialization 97.3 (8.7) 101.1 (7.4) .113
SEQ hyporesponsivenessd 11.6 (9.3) 9.3 (2.0) .226
SEQ hyperresponsiveness 24.9 (5.6) 24.4 (4.3) .730
SEQ seeking* 32.8 (9.9) 22.2 (12.5) .003
CSBS-parent report totale 96.7 (14.9) 98.5 (14.0) .672
CSBS-parent emotion and eye gazef 10.9 (3.12) 11.3 (2.23) .611
CBSB-parent-communication 10.9 (4.57) 11.3 (2.92) .718
CSBS-parent-gestures* 11.2 (3.98) 13.6 (4.12) .050
CSBS-parent-sounds 9.6 (3.92) 11.0 (3.75) .219
CSBS-parent-words 11.2 (3.45) 11.1 (2.93) .915
CSBS-parent-understanding 9.0 (3.33) 9.7 (3.42) .484
CSBS-parent-object use 9.7 (3.34) 9.4 (2.75) .737
CSBS-parent-social 10.5 (3.29) 11.1 (2.77) .500
CSBS-parent-speech 9.5 (3.40) 9.9 (3.42) .691
CSBS-parent_symbolic 8.9 (2.71) 9.1 (2.98) .813
CSBS-direct total 88.3 (12.7) 89.9 (10.0) .631
CSBS-direct-emotion and eye gaze* 8.8 (2.59) 10.7 (3.61) .049
CBSB-direct-communication 8.8 (3.27) 8.7 (2.13) .900
CSBS-direct-gestures* 8.3 (2.52) 10.0 (2.00) .013
CSBS-direct-sounds 8.3 (1.89) 9.1 (2.17) .190
CSBS-direct-words* 10.3 (2.50) 8.9 (2.05) .041
CSBS-direct-understanding 9.1 (3.00) 7.9 (2.22) .122
CSBS-direct-object use 7.4 (2.63) 7.2 (2.96) .809
CSBS-direct-social 8.4 (2.52) 9.6 (1.80) .064
CSBS-direct-speech 8.8 (2.60) 8.9 (2.00) .882
CSBS-direct-symbolic 7.4 (2.17) 7.1 (2.59) .674
aMullen ELC = Early Learning Composite; mean = 100, SD = 15
bMullen GM = gross motor; FM = fine motor; VR = visual reception; RL = receptive language; EL = expressive language; mean = 50, SD = 10
cVABS-II ABC = Vineland Adaptive Behavior Composite; mean for all VABS-II scales = 100, SD = 15
dSEQ=Sensory ExperiencesQuestionnaire; hyporesponsiveness referencemean=8.7 (1.9); hyperresponsiveness referencemean=24.1 (4.6); seeking referencemean=29.7 (8.7) [76]
eCSBS total = Communication Symbolic Behavior Scale; mean = 100, SD = 15
fCSBS subscales (emotion and eye gaze, communication, gestures, sounds, words, understanding, object use, social, speech, symbolic); mean = 10, SD = 3
*significant difference between groups
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related to increased risk for attention, anxiety, or autism
symptoms reported for older individuals.
Infants with the premutation were found across all as-
sessment points to be more sensory seeking than their
matched screen-negative peers. They were also rated to
be more hyporesponsive to sensory stimuli at all ages
tested. Hyporesponsivity refers to a lack of or reduced
intensity in response to external stimuli. For example, a
hyporesponsive infant may not react to loud sounds or
may appear to have a very high pain threshold. Patterns
of increased hyporesponsivity have been associated with
increased risks for autism in both toddlers [52] and older
children [53, 54]. Specifically, hyporesponsivity is more
strongly associated with the core autism symptoms of
social and communication impairments than with re-
petitive behaviors [55], which are generally more related
to hyperresponsivity [56]. Interestingly, the premutation
group also became more hyperresponsive over time,
whereas the control group became less hyperresponsive
as they got older. Hyperresponsivity is used to describe a
pattern of exaggerated responses to sensory stimuli—for
example avoiding touch or covering ears to block
sounds. Individuals with FXS are often described as
being hyporesponsive in the first year of life and then
become hyperresponsive and hyperaroused in response
to external stimuli after the second or third year of life
[57]. The hyperresponsive behavior is thought to be re-
lated to a lack of GABA inhibition which causes a lack
of habituation to sensory stimuli seen in children with
FXS [58]. GABA deficits have not only been documented
in FXS but also in those with the premutation [59].
This pattern of both hyporesponsiveness and increas-
ing hyperresponsiveness may appear counterintuitive;
however, some literature suggests that this co-existing
pattern is more common among children with develop-
mental differences, especially autism symptoms [43, 57,
60]. Although it is not uncommon to observe a pattern
of co-occurring hyper- and hyporesponsivity in children
with developmental differences, other studies have noted
that hyperresponsivity may be more strongly related to
mental age [53], while hyporesponsivity is more strongly
related to core autism features [43], which may explain
the co-occurrence in very young cohorts. However, ac-
cording to the dynamic theory of sensory processing
[61], individual responses to stimuli and experiences are
partially influenced by two thresholds—one related to
Table 4 Parameter estimates and (standard errors) for early development (Mullen, VABS-II), communication (CSBS), and sensory
issues (SEQ hyper, hypo, and seeking)
Effect Intercept Group Age Group × age
Mullen ELC 98.43 (2.88) 4.31 (4.27) .12 (.15) −.02 (.25)
VABS-II ABC 98.11 (2.05) 1.88 (2.96) .11 (.11) .13 (.19)
CSBS-emotion and eye gaze 10.92 (.77) 1.12 (1.14) −.31 (.09)** .41 (.16)*
SEQ-hyporesponsive 10.96 (.50) −1.51 (.79)* .02 (.04) .00 (.07)
SEQ-hyperresponsive 24.96 (.66) −.93 (1.06) −.11 (.05)* −.21 (.09)*
SEQ-seeking 31.29 (1.32) 1.64 (2.11) −.25 (.1) −.28 (.07)
*p < .05; **p < .01
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Fig. 1 CSBS parent report emotion and eye gaze scaled scores by age and diagnosis
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orienting to stimuli (orienting threshold) and one as-
sociated with tolerance for stimuli (aversion thresh-
old). When in the optimal band of stimulation
between orienting and aversion thresholds, an individ-
ual is the most capable of attending and engaging. The
wider the band between these two thresholds, the
greater the person is at adapting to their environment.
A hyporesponsive individual will have a higher thresh-
old for orienting (i.e., require more intense input from
a stimulus to perceive and attend). Conversely, a hy-
perresponsive person will have a lower threshold for
aversion (i.e., require less intense stimulus to become
averse). An individual who is both hypo- and hyperre-
sponsive therefore will have a narrower optimal band
of stimulation from which to engage with their world
[62]. This pattern may affect the individual’s ability to
communicate and interact appropriately with others,
leading to increases in anxiety, attention, or autism-
like symptoms.
Babies with the premutation also demonstrated ele-
vated social-communication problems as measured by
the parent reported CSBS (fewer gestures) and the
CSBS direct assessment (fewer gestures, worse emotion
and eye gaze). Further, consistent with studies of older
individuals with the premutation, just over a third of
infants in this study had social-communication difficul-
ties as measured by the parent-reported FYI and the
direct assessment on the ADOS-2. The FYI was devel-
oped specifically to assess the presence of behaviors at
12 months associated with the later development of an
ASD [45]. However, it is also a sensitive tool for identi-
fying early non-ASD developmental differences [63].
Therefore, while elevated scores do not suggest a clear
trajectory toward an autism diagnosis, they do suggest
increased risk for social communication challenges or
other developmental delays.
Gender differences are generally expected given the
FMR1 is located on the X chromosome and females,
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with two X chromosomes, can have a more variable
phenotype based on the X-activation ratio (percent of
cells with the normal allele on the active X chromo-
some). We did not find any gender differences on any of
our variables of interest. Unfortunately, we did not have
additional molecular data (e.g., activation ratio), which
could be an important addition to understanding poten-
tial gender differences among premutation carriers.
Why some individuals with the premutation develop
cognitive, psychiatric, or medical problems and others
do not is a key question for FMR1 researchers. In the
current sample, higher CGG repeats in the infants were
associated with lower developmental scores on the Mul-
len but not on any of the variables where there was a
significant difference from the comparison group. CGG
repeat length has been implicated in the onset and se-
verity of several associated features, although the rela-
tionship is still unclear. Higher CGG repeats in the
premutation range are associated with lower levels of
FMRP [64, 65], as well as increases in FMR1 messenger
ribonucleic acid (mRNA) levels [66, 67], both of which
disrupt normal neuronal functioning. However, while
some studies suggest a linear association, particularly for
neurological problems (e.g., higher CGG repeats associ-
ated with more problems) [22, 66, 68], others have found
a nonlinear association (particularly for ovarian or psy-
chiatric problems) with greater severity among those
with a CGG repeat number in the mid-premutation
range [29, 69–74]. Additional genetic abnormalities
(copy number variation) have been found in 20 % of car-
riers who have ASD or neurological problems [75], and
these may have an additive effect, leading to a more se-
vere phenotype. Another possibility is that carriers have
a genetic susceptibility to stress [73] which may result in
greater impact of every day stressors on the developing
brains of these infants. These studies suggest that both
molecular and gene-by-environment interaction studies
are needed to fully understand who, among premutation
carriers, is at greatest risk.
There are several limitations to this study and associ-
ated alternative explanations for our findings. Although
larger than any other study examining infants with an
FMR1 premutation, our findings are still limited by the
small sample size. We were underpowered for some of
our analyses, especially with the decreasing number of
control subjects in older ages. The small sample size and
large number of variables does increase the chances for
false discoveries, and this is an important limitation to
keep in mind. However, in the areas where significant
differences were found, the comparison sample tracked
along with what would be expected based on norming
samples for the instruments, whereas significant differ-
ences were observed for the premutation sample. Fur-
ther, the variation in developmental trajectories found in
the premutation infants is not inconsistent with findings
for older individuals with a premutation, where develop-
mental differences, especially in social and executive
function domains, have been reported in a subsample
[16, 18, 19, 30]. Therefore, we argue that our findings
from this relatively large, unbiased sample of premuta-
tion infants establish an important basis for examining
potential molecular and environmental factors which
may influence outcomes for individuals with a premuta-
tion very early in life.
Although all screen-positive families from the new-
born screening study were given the same opportunity
to participate, it is possible that more families who had
concerns about their child were willing to participate in
the study over time, thereby reducing generalizability of
the results. However, in our experience, more dysfunc-
tional families tended not to want to participate initially,
perhaps biasing the study to higher functioning children.
Further, although we were obviously not able to follow
the development of those who did not participate, there
were no significant differences in family- or child-level
variables of those who did not continue in the study
after their first assessment and those who were followed
for a longer period of time.
In addition, some significant results may be due to
parents of the premutation babies being more sensitive
to subtle differences as a result of increased anxiety on
their part as to the impact of the premutation. How-
ever, parents did not report significant differences on
any of the broad areas of development or temperament
traits. Rather, differences were found in areas that
might be expected for children with early regulation
difficulties associated with later anxiety, hyperactivity,
and other social-emotional challenges. Further, we
found significant differences between groups on the direct
assessment of the CSBS, which was scored by experts
blind to diagnostic group. Finally, these are the same dif-
ferences commonly reported among larger samples of
older individuals with a premutation, suggesting there
may be increased risks for some individuals with a premu-
tation which begin very early in life.
Conclusions
This study is the first to report on developmental trajec-
tories of infants and toddlers with an FMR1 premutation
and no family history of FXS. Results from this study
support the emerging discussion of an endophenotype
for individuals on the spectrum of FMR1 involve-
ment—with increased risk for a subset of premutation
carriers. Additional genotype-phenotype studies are
needed to help identify which FMR1 premutation car-
riers are at greater risk in order to inform the develop-
ment of early, supportive interventions to reduce
negative outcomes.
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